O. Khan, FRCS, Research Fellow in Urology.
Prostacyclin in Prostatic Cancer: A Better Marker than Bone Scan or Serum Acid Phosphatase?
Article first published online: 26 NOV 2008
© 1982 British Association of Urological Surgeons
British Journal of Urology
Volume 54, Issue 1, pages 26–31, February 1982
How to Cite
KHAN, O., HENSBY, C. N. and WILLIAMS, G. (1982), Prostacyclin in Prostatic Cancer: A Better Marker than Bone Scan or Serum Acid Phosphatase?. British Journal of Urology, 54: 26–31. doi: 10.1111/j.1464-410X.1982.tb13506.x
Read at the 37th Annual Meeting of the British Association of Urological Surgeons in London, July 1981.
- Issue published online: 26 NOV 2008
- Article first published online: 26 NOV 2008
Summary— Prostaglandins have been implicated in the development and spread of malignant tumours. Gas chromatography and mass spectrometry (GC-MS) analysis of prostaglandins in benign and malignant prostatic tissue showed that prostacyclin (PGI2), a prostanoid known to induce bone resorption, was the major component. PGI2 is hydrolysed to 6-oxo-PGF1a. Plasma levels of 6-oxo-PFG1a were measured as an index of PGI2 formation in patients with benign and malignant prostatic disease.
The mean plasma 6-oxo- level in an age-matched control group was comparable to that of patients with benign prostatic hypertrophy. A significant elevation was found in patients with a TO carcinoma (P<0.05). Plasma 6-oxo- levels rise with advancing disease and the concentration varied with the degree of tumour differentiation. Plasma 6-oxo- levels were a more accurate monitor of disease progression than tartrate labile acid phosphatase in patients with M1 carcinoma. Persistently elevated levels were associated with a bad prognosis.